NEWS AND MEDIA
Recent News
Confirmed Plan of Reorganization Facilitates Creation of New Company – “Knoa Pharma”
Dedicated to the public good, Knoa Pharma will deliver billions of dollars of value to communities across the country affected by the opioid crisis Knoa Pharma will apply its scientific expertise to develop and distribute opioid addiction treatment and overdose…
Plan of Reorganization of Purdue Pharma L.P. Receives Bankruptcy Court Approval
Overwhelmingly supported Plan will deliver billions in value to communities across the country to fund programs specifically for abatement of the opioid crisis. Plan crafted and shaped by multiple fiduciaries for the victims, governments, and creditors determined to…
Purdue Pharma L.P. Announces Preliminary Voting Results on Plan of Reorganization
Creditors overwhelmingly support confirmation of the Plan
STAMFORD, Ct. – Purdue Pharma L.P. today announced preliminary voting results that show overwhelming support for its chapter 11 plan of reorganization (“The Plan”). More than 95% of the 120,000-plus votes submitted were in favor of confirmation. Out of almost 5,000…
FDA Accepts Filing of Abbreviated New Drug Application and Grants Priority Review for Nalmefene HCl Injection for the Treatment of Known or Suspected Opioid Overdose
Stamford, Conn., June 10, 2021 – Purdue Pharma L.P. (“Purdue”) announced that FDA has accepted and granted priority review to the company’s Abbreviated New Drug Application for the vial dosage form of nalmefene hydrochloride injection. Injectable nalmefene, an opioid…
Purdue Pharma L.P. to Begin Soliciting Votes for its Broadly Supported Chapter 11 Plan of Reorganization
STAMFORD, Conn. – [May 3, 2021] – Purdue Pharma L.P. today announced that the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) has approved, among other things, the adequacy of Purdue’s disclosure statement (the “Disclosure…
Purdue Pharma L.P. Files Broadly Supported Plan of Reorganization
Plan will create National Opioid Abatement Trust Plan will make more than $10 billion in value available for opioid abatement programs across the country 100% of Purdue’s assets will be transferred to a new company dedicated at its core to addressing the opioid crisis…
Former Montana Governor Steve Bullock to Monitor Purdue’s Compliance With Voluntary Injunction
STAMFORD, Conn. – March 1, 2021 – Purdue Pharma L.P. (“Purdue”) today announced the appointment of former Montana Governor Steve Bullock as Monitor to report quarterly to the Bankruptcy Court and Purdue’s board on the company’s compliance with its voluntary…
Purdue Pharma Reaches Agreement With U.S. Department of Justice
-- Agreement resolves DOJ investigations into past marketing practices -- Settlement funds primarily directed to state, local and tribal governments for opioid crisis abatement purposes -- Agreement brings Purdue closer to its ultimate goal of delivering more than $10…
Prescription Drug Safety Network Doubles Student Reach During the 2019-2020 Academic Year
-- 80 percent of students in Purdue Pharma’s sponsored regions reported they felt prepared to avoid prescription drug misuse after completing the course -- In response to an increase in distance learning, Prescription Drug Safety course is now available outside of…
Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Development of Over-the-Counter Opioid Overdose Reversal Medication
Lower cost, more accessible medication will help save lives Purdue Pharma L.P. and Harm Reduction Therapeutics, Inc. (HRT) announced today that Purdue will provide up to $6.5 million of additional financial support to HRT to advance its development of a low-cost,…